Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.